vedomostiregmedРегуляторные исследования и экспертиза лекарственных средствRegulatory Research and Medicine Evaluation3034-30623034-3453Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)10.30895/1991-2919-2022-12-4-444-454vedomostiregmed-510Research ArticleДИАГНОСТИКА ЗАБОЛЕВАНИЙDISEASE DIAGNOSTICSРоль ПЭТ/КТ с 18F-ФДГ в диагностике рака шейки матки18F-FDG PET/CT in the Diagnosis of Cervical Cancerhttps://orcid.org/0000-0002-4282-0192ЛеонтьевА. В.LeontyevA. V.

Леонтьев Алексей Викторович, канд. мед. наук.

125284, Москва, 2-й Боткинский проезд, д. 3

Alexey V. Leontyev, Cand. Sci. (Med.)

125284, Moscow, 2nd Botkinsky Dr., 3

aleksleont@yandex.ruhttps://orcid.org/0000-0002-2172-5778ХоджибековаМ. М.KhodzhibekovaM. M.

Ходжибекова Малика Маратовна, д-р мед. наук.

125284, Москва, 2-й Боткинский проезд, д. 3

Malika M. Khodzhibekova, Dr. Sci. (Med.)

125284, Moscow, 2nd Botkinsky Dr., 3

malika_25@mail.ruhttps://orcid.org/0000-0002-8905-4202ХалимонА. И.KhalimonA. I.

Халимон Александр Игоревич

125284, Москва, 2-й Боткинский проезд, д. 3

Aleksandr I. Khalimon

125284, Moscow, 2nd Botkinsky Dr., 3

markyhaws@gmail.comhttps://orcid.org/0000-0002-3508-1782КулиевМ. Т.KulievM. T.

Кулиев Магомед Темирланович

125284, Москва, 2-й Боткинский проезд, д. 3

Magomed T. Kuliev

125284, Moscow, 2nd Botkinsky Dr., 3

kul502@yandex.ruhttps://orcid.org/0000-0002-4864-0643ХамадееваГ. Ф.KhamadeevaG. F.

Хамадеева Гульнара Фаридовна

125284, Москва, 2-й Боткинский проезд, д. 3

Gulnara F. Khamadeeva

125284, Moscow, 2nd Botkinsky Dr., 3

gulnara116@yandex.ruhttps://orcid.org/0000-0002-1255-2991АнтоневскаяТ. Л.AntonevskayaT. L.

Антоневская Тамара Леонтьевна

125284, Москва, 2-й Боткинский проезд, д. 3

Tamara L. Antonevskaya

125284, Moscow, 2nd Botkinsky Dr., 3

dtamara.doc@gmail.comhttps://orcid.org/0000-0002-7835-4939ЛазутинаТ. Н.LazutinaT. N.

Лазутина Татьяна Николаевна, канд. мед. наук

125284, Москва, 2-й Боткинский проезд, д. 3

Tatyana N. Lazutina, Cand. Sci. (Med.)

 125284, Moscow, 2nd Botkinsky Dr., 3

t.n.lazutina@yandex.ruhttps://orcid.org/0000-0001-8784-8415КапринА. Д.KaprinA. D.

Каприн Андрей Дмитриевич, д-р мед. наук, профессор, академик РАН

249031, Обнинск, ул. Королева, д. 4

Andrey D. Kaprin, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

249031, Obninsk, Korolev St., 4

kaprin@mail.ruМосковский научный исследовательский онкологический институт имени П.А. Герцена — филиал Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской ФедерацииРоссияP. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological CentreRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Radiological CentreRussian Federation202203112022124444454Copyright © Леонтьев А.В., Ходжибекова М.М., Халимон А.И., Кулиев М.Т., Хамадеева Г.Ф., Антоневская Т.Л., Лазутина Т.Н., Каприн А.Д., 20222022Леонтьев А.В., Ходжибекова М.М., Халимон А.И., Кулиев М.Т., Хамадеева Г.Ф., Антоневская Т.Л., Лазутина Т.Н., Каприн А.Д.Leontyev A.V., Khodzhibekova M.M., Khalimon A.I., Kuliev M.T., Khamadeeva G.F., Antonevskaya T.L., Lazutina T.N., Kaprin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vedomostincesmp.ru/jour/article/view/510

Позитронная эмиссионная томография, совмещенная с компьютерной томографией (ПЭТ/КТ), доказала свою высокую информативность в диагностике различных злокачественных опухолей. При ПЭТ/КТ исследовании учитываются биологические и морфологические данные, что позволяет точно локализовать распространенность процесса и, соответственно, полноценно определить стадию заболевания. Одним из наиболее распространенных онкологических заболеваний у женщин является характеризующийся высокой смертностью рак шейки матки (РШМ). Эффективность лечения РШМ зависит от ранней диагностики, которая непосредственно связана с оценкой местной распространенности опухоли и метастатического поражения лимфатических узлов до лечения, а также выявлением рецидива заболевания. Цель работы — анализ возможностей метода ПЭТ/КТ с 18F-ФДГ и другими радиофармацевтическими лекарственными средствами (РФЛС) в диагностике РШМ, оценке эффективности терапии, а также рассмотрение перспектив применения других РФЛС в качестве биомаркеров ответа опухоли на терапию. Злокачественные новообразования шейки матки обладают высокой гликолитической активностью, поэтому применение ПЭТ/КТ с 18F-ФДГ в комплексной диагностике пациентов с РШМ превосходит другие традиционные методы визуализации, в особенности в выявлении поражения лимфатических узлов, обнаружении отдаленных метастазов. Кроме того, доказана важная роль ПЭТ/КТ в оценке эффективности лечения РШМ. Дальнейшие перспективы развития ПЭТ/КТ в визуализации злокачественного поражения шейки матки связаны с изучением возможностей применения других специфичных радиофармацевтических лекарственных средств для получения информации о биологических процессах, являющихся основой роста опухолевой клетки — метаболизме, пролиферативной активности, оксигенации.

Positron emission tomography coupled with computed tomography (PET/CT) has proven to be highly informative in the diagnosis of various malignant tumours. PET/CT examination takes into account biological and morphological data, which allow accurate tumour localisation and full staging of the disease, respectively. Cervical cancer (CC) is one of the most common, high-mortality cancers in women. The effectiveness of CC treatment depends on early diagnosis, which is connected to the assessment of local tumour spread and metastatic lymph node involvement and to the  detection of disease recurrence. The aim of the study was to  analyse the possibility of using PET/CT with 18F-FDG for the diagnosis of CC and the evaluation of treatment effectiveness. Additionally, the study aimed to analyse the potential of using other radiopharmaceuticals as biomarkers for the assessment of tumour response. Cervical malignancies are characterised by high glycolytic activity, which explains the superiority of 18F-FDG PET/CT over other traditional imaging methods in comprehensive diagnosis of patients with CC and, especially, in detecting nodal involvement and distant metastases. Also, 18F-FDG PET/CT plays an important part in the assessment of treatment effectiveness in CC patients. Further development of 18F-FDG PET/CT potential in the visualisation of malignant cervical lesions is associated with investigating the possibilities of using other specific radiopharmaceuticals to obtain information about the biological processes that support tumour cell growth: metabolism, proliferative activity, and oxygenation.

ПЭТ/КТ18F-ФДГрадиофармацевтическое лекарственное средстворак шейки маткиPET/CT18F-FDGradiopharmaceutical productcervical cancerReferencesАксель ЕМ. Статистика злокачественных новообразований женской половой сферы. Онкогинекология. 2012;(1):18–23.Aksel EM. Statistics of malignant tumors of female reproductive system. Onkoginekologiya = Oncogynecology. 2012;(1):18–23 (In Russ.)Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, et al. Cervical cancer, version 2.2015. J Natl Compr Canc Netw. 2015;13(4):395–404. https://doi.org/10.6004/jnccn.2015.0055Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, et al. Cervical cancer, version 2.2015. J Natl Compr Canc Netw. 2015;13(4):395–404. https://doi.org/10.6004/jnccn.2015.0055Stanley M. Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol). 2008;20(6):388–94. https://doi.org/10.1016/j.clon.2008.04.006Stanley M. Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol). 2008;20(6):388–94. https://doi.org/10.1016/j.clon.2008.04.006Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71–96. https://doi.org/10.3322/CA.2007.0010Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71–96. https://doi.org/10.3322/CA.2007.0010Grigsby PW. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging. 2008;8(1):146–55. https://doi.org/10.1102/1470-7330.2008.0022Grigsby PW. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging. 2008;8(1):146–55. https://doi.org/10.1102/1470-7330.2008.0022Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstet Invest. 2017;82(3):209–22. https://doi.org/10.1159/000456006Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstet Invest. 2017;82(3):209–22. https://doi.org/10.1159/000456006Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47(1):28–50. https://doi.org/10.1007/s00259-019-04553-8Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47(1):28–50. https://doi.org/10.1007/s00259-019-04553-8Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, et al. Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol. 2020;15(1):88. https://doi.org/10.1186/s13014-020-01519-1Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, et al. Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol. 2020;15(1):88. https://doi.org/10.1186/s13014-020-01519-1Zytoon AA, Elsayed EE, Nassar AI, Koji M. Pivotal role of PET/CT in characterization of occult metastasis with undetermined origin. Egypt J Radiol Nucl Med. 2020;51: 240. https://doi.org/10.1186/s43055-020-00357-1Zytoon AA, Elsayed EE, Nassar AI, Koji M. Pivotal role of PET/CT in characterization of occult metastasis with undetermined origin. Egypt J Radiol Nucl Med. 2020;51: 240. https://doi.org/10.1186/s43055-020-00357-1Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, et al. Appropriate use criteria for <sup>18</sup>F-FDG PET/CT in restaging and treatment response assessment of malignant disease. J Nucl Med. 2017;58(12):2026–37. https://doi.org/10.2967/jnumed.117.197988Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, et al. Appropriate use criteria for <sup>18</sup>F-FDG PET/CT in restaging and treatment response assessment of malignant disease. J Nucl Med. 2017;58(12):2026–37. https://doi.org/10.2967/jnumed.117.197988Shahhosseini S. PET Radiopharmaceuticals. Iran J Pharm Res. 2011;10(1):1–2. https://doi.org/10.22037/ijpr.2010.890Shahhosseini S. PET Radiopharmaceuticals. Iran J Pharm Res. 2011;10(1):1–2. https://doi.org/10.22037/ijpr.2010.890Rajendran J, Mankoff D. Positron emission tomography imaging of hypoxia and blood flow in tumors. Cancer Drug Discovery and Development. In Vivo Imaging of Cancer Therapy. 2006;(4):47–71.Rajendran J, Mankoff D. Positron emission tomography imaging of hypoxia and blood flow in tumors. Cancer Drug Discovery and Development. In Vivo Imaging of Cancer Therapy. 2006;(4):47–71.Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of <sup>64</sup>Cu-ATSM and <sup>60</sup>Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008;49(7):1177–82. https://doi.org/10.2967/jnumed.108.051326Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of <sup>64</sup>Cu-ATSM and <sup>60</sup>Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008;49(7):1177–82. https://doi.org/10.2967/jnumed.108.051326Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol. 2010;73(3): 461–9. https://doi.org/10.1016/j.ejrad.2009.12.022Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol. 2010;73(3): 461–9. https://doi.org/10.1016/j.ejrad.2009.12.022Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45(1):22–9. PMID:14734665Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45(1):22–9. PMID:14734665Rudlowski C, Becker AJ, Schroder W, Rath W, Büttner R, Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol. 2003;120(5):691–8. https://doi.org/10.1309/4KYN-QM58-62JW-2GD7Rudlowski C, Becker AJ, Schroder W, Rath W, Büttner R, Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol. 2003;120(5):691–8. https://doi.org/10.1309/4KYN-QM58-62JW-2GD7Bar JK, Harłozińska A, Sedlaczek P, Kasiak J, Markowska J. Relations between the expression of p53, c-erbB-2, Ki-67 and HPV infection in cervical carcinomas and cervical dysplasias. Anticancer Res. 2001;21(2A):1001–6. PMID: 11396132Bar JK, Harłozińska A, Sedlaczek P, Kasiak J, Markowska J. Relations between the expression of p53, c-erbB-2, Ki-67 and HPV infection in cervical carcinomas and cervical dysplasias. Anticancer Res. 2001;21(2A):1001–6. PMID: 11396132Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35(12):2320–33. https://doi.org/10.1007/s00259-008-0874-2Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35(12):2320–33. https://doi.org/10.1007/s00259-008-0874-2Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200. https://doi.org/10.1007/s00259-009-1297-4Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200. https://doi.org/10.1007/s00259-009-1297-4Herrera F, Prior J. The role of PET/CT in cervical cancer. Front Oncol. 2013;3:34. https://doi.org/10.3389/fonc.2013.00034Herrera F, Prior J. The role of PET/CT in cervical cancer. Front Oncol. 2013;3:34. https://doi.org/10.3389/fonc.2013.00034Mirpour S, Mhlanga J, Logeswaran P, Russo G, Mercier G, Subramaniam RM. The role of PET/CT in the management of cervical cancer. AJR Am J Roentgenol. 2013; 201(2):W192–205. https://doi.org/10.2214/ajr.12.9830Mirpour S, Mhlanga J, Logeswaran P, Russo G, Mercier G, Subramaniam RM. The role of PET/CT in the management of cervical cancer. AJR Am J Roentgenol. 2013; 201(2):W192–205. https://doi.org/10.2214/ajr.12.9830Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606–13. https://doi.org/10.1200/JCO.2000.18.8.1606Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606–13. https://doi.org/10.1200/JCO.2000.18.8.1606Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73(2):177–83. https://doi.org/10.1006/gyno.1999.5387Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73(2):177–83. https://doi.org/10.1006/gyno.1999.5387Nogami Y, Iida M, Banno K, Kisu I, Adachi M, Nakamura K, et al. Application of FDG-PET in cervical cancer and endometrial cancer: utility and future prospects. Anticancer Res. 2014;34(2):585–92. PMID:24510987Nogami Y, Iida M, Banno K, Kisu I, Adachi M, Nakamura K, et al. Application of FDG-PET in cervical cancer and endometrial cancer: utility and future prospects. Anticancer Res. 2014;34(2):585–92. PMID:24510987Mirpour S, Mhlanga JC, Logeswaran P, Russo G, Mercier G, Subramaniam RM. The role of PET/CT in the management of cervical cancer. AJR Am J Roentgenol. 2013;201(2):W192–205. https://doi.org/10.2214/AJR.12.9830Mirpour S, Mhlanga JC, Logeswaran P, Russo G, Mercier G, Subramaniam RM. The role of PET/CT in the management of cervical cancer. AJR Am J Roentgenol. 2013;201(2):W192–205. https://doi.org/10.2214/AJR.12.9830Ruan J, Zhang Y, Ren H. Meta-analysis of PET/CT detect lymph nodes metastases of cervical cancer. Open Med (Wars). 2018;13:436–42. https://doi.org/10.1515/med-2018-0065Ruan J, Zhang Y, Ren H. Meta-analysis of PET/CT detect lymph nodes metastases of cervical cancer. Open Med (Wars). 2018;13:436–42. https://doi.org/10.1515/med-2018-0065Wright JD, Dehdashti F, Herzog TJ, Mutch DG, Huettner PC, Rader JS, et al. Preoperative lymph node staging of early-stage cervical carcinoma by [<sup>18</sup>F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer. 2005;104(11):2484–91. https://doi.org/10.1002/cncr.21527Wright JD, Dehdashti F, Herzog TJ, Mutch DG, Huettner PC, Rader JS, et al. Preoperative lymph node staging of early-stage cervical carcinoma by [<sup>18</sup>F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer. 2005;104(11):2484–91. https://doi.org/10.1002/cncr.21527Magné N, Chargari C, Vicenzi L, Gillion N, Messai T, Magné J, et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev. 2008;34(8):671–81. https://doi.org/10.1016/j.ctrv.2008.08.003Magné N, Chargari C, Vicenzi L, Gillion N, Messai T, Magné J, et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev. 2008;34(8):671–81. https://doi.org/10.1016/j.ctrv.2008.08.003Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2-[<sup>18</sup>F]fluoro-Dglucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol. 2004;6(1):55–62. https://doi.org/10.1016/j.mibio.2003.12.004Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2-[<sup>18</sup>F]fluoro-Dglucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol. 2004;6(1):55–62. https://doi.org/10.1016/j.mibio.2003.12.004Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol. 2003;90(3):572–6. https://doi.org/10.1016/s0090-8258(03)00402-5Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol. 2003;90(3):572–6. https://doi.org/10.1016/s0090-8258(03)00402-5Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007;106(1):29–34. https://doi.org/10.1016/j.ygyno.2007.03.027Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007;106(1):29–34. https://doi.org/10.1016/j.ygyno.2007.03.027Wang X, Koch S. Positron emission tomography/computed tomography potential pitfalls and artifacts. Curr Probl Diagn Radiol. 2009;38(4):156–69. https://doi.org/10.1067/j.cpradiol.2008.01.001Wang X, Koch S. Positron emission tomography/computed tomography potential pitfalls and artifacts. Curr Probl Diagn Radiol. 2009;38(4):156–69. https://doi.org/10.1067/j.cpradiol.2008.01.001Amit A, Person O, Keidar Z. FDG PET/CT in monitoring response to treatment in gynecological malignancies. Curr Opin Obstet Gynecol. 2013;25(1):17–22. https://doi.org/10.1097/GCO.0b013e32835a7e96Amit A, Person O, Keidar Z. FDG PET/CT in monitoring response to treatment in gynecological malignancies. Curr Opin Obstet Gynecol. 2013;25(1):17–22. https://doi.org/10.1097/GCO.0b013e32835a7e96Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med. 2009;50(Suppl 1):64S–73S. https://doi.org/10.2967/jnumed.108.057257Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med. 2009;50(Suppl 1):64S–73S. https://doi.org/10.2967/jnumed.108.057257Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [<sup>18</sup>F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22(11):2167–71. https://doi.org/10.1200/JCO.2004.09.035Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [<sup>18</sup>F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22(11):2167–71. https://doi.org/10.1200/JCO.2004.09.035Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014;35(2):144–50. https://doi.org/10.1097/MNM.0000000000000026Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014;35(2):144–50. https://doi.org/10.1097/MNM.0000000000000026Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009;112(1):104–9. https://doi.org/10.1016/j.ygyno.2008.08.028Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009;112(1):104–9. https://doi.org/10.1016/j.ygyno.2008.08.028Emami NA, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62. https://doi.org/10.1186/s12935-020-01719-5Emami NA, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62. https://doi.org/10.1186/s12935-020-01719-5Nordsmark M, Loncaster J, Aquino-Parsons C, Chou SC, Gebski V, West C, et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol. 2006;80(2):123–31. https://doi.org/10.1016/j.radonc.2006.07.010Nordsmark M, Loncaster J, Aquino-Parsons C, Chou SC, Gebski V, West C, et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol. 2006;80(2):123–31. https://doi.org/10.1016/j.radonc.2006.07.010Pinker K, Andrzejewski P, Baltzer P, Polanec SH, Sturdza A, Georg D, et al. Multiparametric [<sup>18</sup>F] fluorodeoxyglucose/[<sup>18</sup>F]fluoromisonidazole positron emission tomography/magnetic resonance imaging of locally advanced cervical cancer for the non-invasive detection of tumor heterogeneity: a pilot study. PLoS One. 2016;11(5):e0155333. https://doi.org/10.1371/journal.pone.0155333Pinker K, Andrzejewski P, Baltzer P, Polanec SH, Sturdza A, Georg D, et al. Multiparametric [<sup>18</sup>F] fluorodeoxyglucose/[<sup>18</sup>F]fluoromisonidazole positron emission tomography/magnetic resonance imaging of locally advanced cervical cancer for the non-invasive detection of tumor heterogeneity: a pilot study. PLoS One. 2016;11(5):e0155333. https://doi.org/10.1371/journal.pone.0155333

The authors declare that there are no conflicts of interest present.